Hedge Fund - Baker Bros. Advisors

Shares of Anacor Pharmaceuticals Inc (NASDAQ:ANAC) soared to a lofty $140.00 per share pre-market high today, or a whopping 65.47% higher than the stock’s closing price of $84.61 on Friday after the...

With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.

Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.

Julian Baker and Felix Baker’s Baker Bros. Advisors recently disclosed an increase of around 929,700 shares to its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX).

As a new filing with the Securities and Exchange Commission showed, Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has been added to the equity portfolio of Julian and Felix Bakers' healthcare-focused hedge...

Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday. The firm continued to boost its exposure to Seattle Genetics, Inc.

In several new filings with the Securities and Exchange Commission, Julian and Felix Bakers' healthcare-focused fund Baker Bros. Advisors reported raising its positions in Seattle Genetics, Inc.

Julian Baker and Felix Baker’s Baker Bros. Advisors is tightening its grip over XenoPort, Inc. (NASDAQ:XNPT) and so is James E. Flynn’s Deerfield Management over CareDx Inc (NASDAQ:CDNA).

As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix Bakers' Baker Bros Advisors, a fund focused on the biotechnology and healthcare companies, have revealed upping...